Time-Restricted High-Dose Melatonin for Acute Neuroprotection
🧪 Overview
Nightly 10mg melatonin dosing attenuates Aβ42-induced neurotoxicity through MT1-mediated suppression of PERK/CHOP apoptotic pathways. However, 10mg produces serum levels 20-100x physiological peaks—fundamentally different from H1's physiological replacement framing. PERK/CHOP pathway studies used micromolar melatonin concentrations (100-500 μM) in cell culture; human CSF after 10mg oral peaks at 1-3 nM. Caspase-12 is predominantly murine—humans have non-functional pseudogene. ADCS melatonin trial found no benefit at doses up to 10mg. This hypothesis requires pharmacokinetic reconciliation and species-specific mechanism validation.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["High-Dose Melatonin 10mg<br/>Nightly Dosing"]
B["MT1 Receptor Activation<br/>Gi-coupled Signaling"]
C["cAMP Reduction<br/>PKA Pathway Modulation"]
D["PERK ER Stress Kinase<br/>Activity Suppression"]
E["eIF2alpha Phosphorylation<br/>Reduction"]
F["CHOP DDIT3 Transcription<br/>Factor Downregulation"]
G["Caspase-12 Apoptosis<br/>Pathway Inhibition"]
H["Abeta42 Neurotoxicity<br/>Resistance"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MT1
No curated PDB or AlphaFold mapping for MT1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for MT1 receptor; CHOP (DDIT3); caspase-12; Bcl-2/Bax from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MT1 receptor; CHOP (DDIT3); caspase-12; Bcl-2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF human iPSC-derived neurons or cerebral organoids are treated with Aβ42 oligomers AND exposed to melatonin concentrations matching human CSF levels after 10mg oral dosing (1-3 nM), THEN we will obse | No statistically significant change in p-PERK/PERK ratio or DDIT3 expression with 1-3 nM melatonin vs. Aβ42 alone; effect size <10% difference between groups | — no observation — | pending | 0.75 |
| IF C57BL/6J mice are subjected to focal cerebral ischemia (60-min MCAO) AND receive time-restricted 10mg/kg melatonin via intraperitoneal injection at reperfusion onset, THEN the neuroprotective effec | Infarct volume reduction >30% in melatonin-treated vs. vehicle mice, but caspase-12 protein will be absent or non-functional in human brain tissue; mouse brain | — no observation — | pending | 0.60 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |